The Trump administration is planning a five-year experiment that would allow some obese Americans on Medicare and Medicaid to access expensive weight loss drugs. The proposed plan would give state Medicaid programs and Medicare Part D insurance plans the option to cover drugs like Ozempic, Wegovy, Mounjaro, and Zepbound for weight management purposes. This initiative aims to provide more treatment options for individuals struggling with obesity and related health issues.
Source: https://www.washingtonpost.com/health/2025/08/01/medicare-medicaid-weight-loss-drugs/